CTLA4 and ovarian cancer: Dual blockade of PD-1 and CTLA-4 enhanced efficacy of the GVAX vaccine in ovarian cancer models through activation of CD4 and CD8 T cells, secretion of cytokines, and inhibition of Treg cells (96).